S'abonner

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis - 14/12/12

Doi : 10.1016/j.jaad.2012.06.035 
Howa Yeung, BS a, Joy Wan, BA a, Abby S. Van Voorhees, MD a, Kristina Callis Duffin, MD c, Gerald G. Krueger, MD c, Robert E. Kalb, MD d, Jamie D. Weisman, MD e, Brian R. Sperber, MD, PhD f, Bruce A. Brod, MD a, Stephen M. Schleicher, MD g, Bruce F. Bebo, PhD h, Daniel B. Shin, MS a, b, Andrea B. Troxel, ScD b, Joel M. Gelfand, MD, MSCE a, b,
a Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
b Department of Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
c Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah 
d Department of Dermatology, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York 
e Peachtree Dermatology Associates, Atlanta, Georgia 
f Colorado Springs Dermatology Clinic, Colorado Springs, Colorado 
g DermDox Centers for Dermatology, Hazelton, Pennsylvania 
h National Psoriasis Foundation, Portland, Oregon 

Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, 1471 Penn Tower, One Convention Ave, Philadelphia, PA 19104.

Abstract

Background

Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients’ reasons behind treatment discontinuation remain poorly understood.

Objectives

We sought to characterize patient-reported reasons for discontinuing commonly used treatments for moderate to severe psoriasis in real-world clinical practice.

Methods

A total of 1095 patients with moderate to severe plaque psoriasis from 10 dermatology practices who received systemic treatments completed a structured interview. Eleven reasons for treatment discontinuation were assessed for all past treatments.

Results

A total of 2231 past treatments were reported. Median treatment duration varied by treatment, ranging from 6.0 to 20.5 months (P < .001). The frequency of each cited discontinuation reasons differed by treatment (all P < .01). Patients who received etanercept (odds ratio [OR] 5.19; 95% confidence interval [CI] 3.23-8.33) and adalimumab (OR 2.10; 95% CI 1.20-3.67) were more likely to cite a loss of efficacy than those who received methotrexate. Patients who received etanercept (OR 0.34; 95% CI 0.23-0.49), adalimumab (OR 0.48; 95% CI 0.30-0.75), and ultraviolet B phototherapy (OR 0.21; 95% CI 0.14-0.31) were less likely to cite side effects than those who received methotrexate, whereas those who received acitretin (OR 1.56; 95% CI 1.08-2.25) were more likely to do so. Patients who underwent ultraviolet B phototherapy were more likely to cite an inability to afford treatment (OR 7.03; 95% CI 3.14-15.72).

Limitations

The study is limited by its reliance on patient recall.

Conclusions

Different patterns of treatment discontinuation reasons are important to consider when developing public policy and evidence-based treatment approaches to improve successful long-term psoriasis control.

Le texte complet de cet article est disponible en PDF.

Key words : biologics, cost, effectiveness, inconvenience, phototherapy, psoriasis, safety, systemic treatments, treatment discontinuation

Abbreviations used : DCERN, PUVA, UV


Plan


 Supported by the T32-AR07465 (Mr Yeung, Ms Wan, Mr Shin) and 1KM1CA156723 (Dr Callis Duffin) training grants from the National Institutes of Health, and the RC1-AR058204 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Gelfand). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.
 Disclosure: Dr Van Voorhees has served on advisory boards for Amgen, Abbott, Genentech, Warner Chilcott, and Centocor; as an investigator for Amgen and Genentech; as a consultant for Amgen and Leo Pharma; as a speaker for Amgen, Abbott, and Centocor; and received honoraria from Synta. Dr Callis Duffin has served on advisory boards for Amgen; as a consultant for Amgen and Centocor; as an investigator for Abbott, Amgen, Centocor, and Pfizer; and received payments for lectures from Abbott, Amgen, and Centocor. Dr Krueger has served as a consultant for Abbott, Amgen, and Centocor; had grants from Abbott and Amgen; and received payment for lectures and travel-related expenses from Abbott, Amgen, and Centocor. Dr Kalb has served as a consultant for Abbott, Amgen, Centocor, LEO Pharma, and Stiefel; an investigator for Abbott, Amgen, Astellas, and Centocor; and a speaker for Abbott, Amgen, Centocor, Galderma, LEO Pharma, and Stiefel. Dr Weisman has served as an investigator for Abbott, Braintree Laboratories, Celgene, Cipher Pharmaceuticals, LEO Pharma, Pfizer, Norvartis, and Eli Lily; and received payments for lectures from Abbott and Amgen. Dr Sperber is the medical director of Stephens & Associates, has served as a consultant for Amgen, and had grants or has pending grants from Abbott and Centocor. Dr Bebo is employed by the National Psoriasis Foundation, which receives unrestricted financial support from Amgen, Abbott, Janssen, Stiefel Laboratories, Wyeth, Pfizer, Eli Lilly, Galderma, and PhotoMedex. Dr Gelfand has served as a consultant for Abbott, Amgen, Celgene, Centocor, Novartis, and Pfizer; had grants from Abbott, Amgen, Genentech, Novartis, and Pfizer; and received payment for continuing medical education work related to psoriasis. He received a donation from Amgen to the University of Pennsylvania to further develop Dermatology Clinical Effectiveness Research Network, which was not used for the current study. Mr Yeung, Ms Wan, Dr Brod, Dr Schleicher, Mr Shin, and Dr Troxel have no conflicts of interest to declare.
 Reprints not available from the authors.


© 2012  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 68 - N° 1

P. 64-72 - janvier 2013 Retour au numéro
Article précédent Article précédent
  • Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice
  • Paula P.M. van Lümig, Rieke J.B. Driessen, Wietske Kievit, Jan B.M. Boezeman, Peter C.M. van de Kerkhof, Elke M.G.J. de Jong
| Article suivant Article suivant
  • Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: Correlation with pathologic subtypes, p16INK4a expression, and prognosis
  • Carla Ferrándiz-Pulido, Emili Masferrer, Ines de Torres, Belen Lloveras, Javier Hernandez-Losa, Sergio Mojal, Carlos Salvador, Juan Morote, Santiago Ramon y Cajal, Ramon M. Pujol, Vicente Garcia-Patos, Agustin Toll

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.